Document:

Exhibit 10.1

 

AGREEMENT
TO PURCHASE

PROVISTA
DIAGNOSTICS, INC.

 

This
Agreement (this “Agreement”) is entered into by and between Todos Medical Ltd, a company formed under the laws of
Israel (the “Buyer”), Strategic Investment Holdings, LLC, a Nevada limited liability company (“Shareholder”),
Ascenda BioSciences LLC, a Delaware limited liability company (“Ascenda”) and Provista Diagnostics, Inc., a Delaware
corporation (“Provista”) on the date set forth on the signature page hereto. Shareholder and Ascenda are collectively
referred to as the “Sellers”. The Buyer, Shareholder, Ascenda and Provista are collectively referred to herein as
the “Parties”. Capitalized terms not defined herein shall have the meanings assigned to them in the Agreement.

 

RECITALS:

 

WHEREAS,
the Shareholder is the sole owner of all of the outstanding securities of Ascenda,

 

WHEREAS,
Ascenda is the sole owner of all of 100% of the outstanding securities of Provista;

 

WHEREAS,
Sellers wish to sell the Provista Shares to Buyer, and Buyer wishes to purchase the Provista Shares from Sellers, on the terms
and conditions set forth in this Agreement; and

 

NOW,
THEREFORE, in consideration of and for the mutual promises and covenants contained herein, and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties agree as follows:

 

ARTICLE
1. PURCHASE AND SALE

 

SECTION
1.1 SALE AND PURCHASE OF THE PROVISTA SHARES. Subject to the terms and conditions hereof, Sellers shall sell 3,599 shares
of Preferred Stock and 1,581 shares of Ordinary Stock (collectively the “Provista Shares”) representing 100% of
Provista’ s securities outstanding, to Buyer, and Buyer shall purchase the Provista Shares from Sellers, for the
Purchase Price payable in accordance with Section 1.2 of this Agreement, the Securities Purchase Agreement attached as
Exhibit 2 (the “SPA”), Convertible Promissory Note attached as Exhibit 3 (the “Convertible Note”),
Escrow Agreement attached as Exhibit 4 (the “Escrow Agreement”) and Security Agreement attached as Exhibit 5 (the
“Security Agreement”), each of even date herewith with all exhibits and schedules thereto, and other documents
executed in connection with the transactions contemplated hereby (collectively the “Transaction Documents”) each
attached hereto and incorporated herein and made a part hereof:

 

SECTION
1.2 PURCHASE AND SALE. Buyer shall purchase the Provista Shares for an aggregate purchase price (“Purchase Price”)
of seven million five hundred thousand dollars ($7,500,000) which shall be subject to the following terms:

 

	1.2.1	Cash
    Deposit. On or before April 19, 2021, (the “First Closing Date”), Buyer will deliver a non-refundable
    deposit (the “Cash Deposit”) of One Million Two Hundred Fifty Thousand Dollar ($1,250,000) by wire transfer to
    the Sellers’ bank account as set forth as Exhibit 1.

 

    	-1-

    	 

    

 

	1.2.2	First
    Closing. On or before the First Closing Date, Buyer shall deliver to Sellers or Sellers’ designees such number
    of non-refundable shares of its ordinary stock, par value NIS 0.01 per 836695v.1 share, (the “Todos Deposit Shares”)
    with a Fair Market Value of one million five hundred thousand dollars ($1,500,000) as defined by and set forth in the SPA
    (Attached as Exhibit 2). The Parties agree that the Ordinary Shares shall have a value of $.001 per share, for the purpose
    of this transaction, on the date of execution hereof.
	 	 
	1.2.3	Issuance.
    Upon issuance of the Todos Deposit Shares to Seller at the First Closing, such shares shall be validly issued, fully
    paid and non-assessable.
	 	 
	1.2.4	The
    Second Cash Payment. On or before July 1, 2021 (the “Second Closing Date”), Buyer shall deliver a second
    payment (“Second Cash Payment”) of one million two hundred fifty thousand dollars ($1,250,000) to Sellers by wire
    transfer pursuant to the instructions set forth in Exhibit 1.
	 	 
	1.2.5	The
    Convertible Note. On or before the Second Closing Date, Buyer shall deliver to Sellers or their designees the Convertible
    Note (Attached as Exhibit 3) in the principal amount of three million five hundred thousand dollars ($3,500,000), payable
    by Buyer to Seller.
	 	 
	1.2.6	Secured
    Obligation. Buyer’s obligation to deliver the Second Cash Payment and the Convertible Note to Seller at the
    Second Closing shall be secured by the Provista Shares to be held and released in accordance with the Escrow Agreement and
    all of Provista’ s assets (the “Assets”) pursuant to the terms of the Security Agreement attached as Exhibit
    5.
	 	 
	1.2.7	Extension
    of Second Cash Payment Due Date. Buyer shall have the option of extending the payment of the Second Cash Payment until
    July 15, 2021, by paying the Sellers the additional sum of $250,000 (the “Extension Payment”) on or before the
    Second Closing Date. If the Extension Payment is received by Sellers on or before the Second Closing Date, then Buyer shall
    deliver the Convertible Note on the Second Closing Date and the Second Cash Payment on or before July 15, 2021. In the event
    the Buyer completes the Second Cash Payment, this Extension Payment shall be credited towards the Second Cash Payment.
	 	 
	1.2.8	Break-Up
    Fee. For the avoidance of doubt, at the First Closing, the Sellers shall hold full right, title, and interest in and
    to the Cash Deposit, and the Todos Deposit Shares paid to Sellers or their designees and/or assignees pursuant to Section
    1.2.1 and 1.2.2 hereunder on the First Closing Date free and clear of all rights, liens and encumbrances, without limitation.
    Additionally, as set forth in the Escrow Agreement, should Buyer fail to deliver the Second Cash Payment and/or the Convertible
    Note by the Second Closing Date as required by Section 1.2.4 and 1.2.5, the Escrow Agent shall return the Provista Shares
    to Sellers, and Sellers shall become the sole owners thereof. Buyer acknowledges and agrees that the Sellers, their representatives
    and advisors have devoted significant time and efforts and have incurred significant expenses in reviewing and analyzing the
    terms of this Agreements and the business, assets and operations of the Buyer in connection with the Transaction Documents
    and transactions contemplated hereby. Buyer further agrees and understands that in the event that the Buyer fails to deliver
    the Second Cash Payment and/or the Convertible Note to the Sellers at the Second Closing, the Cash Deposit and the Todos Deposit
    Shares shall be the property of the Sellers, and Sellers shall retain and hold full right, title, and interest in and be the
    sole owners of the Cash Deposit, the Todos Deposit Shares and 100% of the Provista Shares. In such an event, Buyer will have
    absolutely no rights, claims or interest of any type in connection with the Provista Shares, Cash Deposit or Todos Deposit
    Shares or this transaction, regardless of any alleged conduct by Seller or anyone else. Further, in such event Buyer irrevocably
    will be deemed to have canceled this Agreement and relinquished all rights in and to the Provista Shares, Cash Deposit and
    Todos Deposit Shares. In connection with the Provista Shares, Escrow Agent may release the Provista Shares to Sellers on the
    day after the Second Closing Date, unless Buyer has complied with 1.2.4 and 1.2.5 hereof. If this Agreement is not canceled
    and all payments due to Seller at the First Closing are made when required, all of the obligations, conditions and contingencies
    of Sellers hereunder will be deemed satisfied.

 

    	-2-

    	 

    

 

SECTION
1.3 CLOSING. The consummation of the transactions contemplated by this Agreement shall take place virtually at the offices
of Sellers or Sellers’ counsel on the First Closing Date (other than the Second Cash Payment and Convertible Note, which
shall be made on July 1, 2021) after all of the conditions set forth in this Agreement are satisfied or waived in accordance with
this Agreement (other than those conditions that by their terms are to be satisfied by actions taken at or after the First or
Second Closing, but subject to the satisfaction or waiver of such conditions at the First or Second Closing), unless another date,
time or place is mutually agreed to in writing by Sellers and Buyer.

 

	1.3.1	Sellers’
    Deliverables. Sellers shall deliver, or cause to be delivered, at the First Closing:

 

(i)
one or more certificates representing all of the Provista Shares duly endorsed in blank or accompanied by stock powers or other
instruments of transfer duly executed in blank to Buyer shall be delivered to Hamilton & Associates Law Group (the “Escrow
Agent”) and held by Escrow Agent as collateral for the Second Cash Payment and Convertible Note pursuant to the terms of
the “Escrow Agreement” attached hereto as Exhibit 4 and made a part hereof,

(ii)
written resignations of each of the directors, managers and officers, as applicable, of the members of Provista, requested by
Buyer effective as the First Closing Date,

(iii)
this Agreement, and other Transaction Documents to which each Seller is a party, duly executed by such Seller, as applicable,
and

(iv)
all other documents, instruments and writings required by this Agreement to be delivered by Sellers at the First Closing.

 

	1.3.2	Buyer
    Deliverables. Buyer shall deliver, or cause to be delivered, to Sellers as follows:

 

(i)
the Cash Deposit on or before the First Closing Date, by wire transfer to the bank account designated by Sellers in Exhibit 1
immediately available funds in an amount equal to the Cash Deposit,

(ii)
at the First Closing, one or more certificates representing all of the Todos Deposit Shares duly endorsed in blank or accompanied
by stock powers or other instruments of transfer duly executed in blank to Sellers’ Designees,

(iii)
at the First Closing, each Transaction Document to which Buyer is a party,

(iv)
all other documents, instruments and writings required by this Agreement to be delivered by Buyer at the First Closing; and

(v)
the Second Cash Payment and Convertible Note on or before the Second Closing Date.

 

    	-3-

    	 

    

 

SECTION
1.4 ASSUMPTION OF LIABILITIES. At or prior to the First Closing, Buyer shall assume all liabilities of Provista, without limitation.
In connection therewith, Buyer agrees to use reasonable best efforts to cause the Landlord to release Charles W. Stout III from
any obligations or liabilities as guarantor under the lease agreement between Diagnostic Reference Group, LLC and Windward Campus
Owner, LLC dated the 29th day of November 2012 for space at 2001Westside Parkway, Unit # 290, Alpharetta, GA 30004 presently occupied
by Provista, which has been modified by addendum (the “Addendum”) to STE 240 (the “Lease”) within thirty
(30) days of the execution of this Agreement. Until Charles W. Stout III is released from the Lease, Buyer shall accept and assume
all obligations or liabilities of Charles W. Stout III, Ascenda BioSciences, LLC, Strategic Investment Holdings LLC, Strategic
Funding, Inc. and related entities associated with the Lease and its Addendum.

 

SECTION
1.5 INDEMNIFICATION OF CHARLES W. STOUT III, ASCENDA BIOSCIENCES, LLC, STRATEGIC FUNDING, INC. AND RELATED ENTITIES.
Subject to the Second Closing Date, Buyer agrees to indemnify, defend and hold Charles W. Stout III, Ascenda BioSciences,
LLC, Strategic Investment Holdings LLC, Strategic Funding, Inc. and related entities harmless from and against any and all
claims, rent payments, demands, causes of action, charges, judgments, damages, liabilities, costs or expenses (including,
without limitation attorneys’ fees and legal costs) arising out or relating directly or indirectly to the Lease, as
amended or the Addendum.

 

SECTION
1.6 INDEMNIFICATION OF BUYER. Sellers, on a joint and several basis, hereby agrees to indemnify, defend and hold harmless
the Buyer from and against any and all Losses sustained or incurred by the Buyer arising from or related to any (i) breach of
any of the representations and warranties of the Sellers and (ii) any liabilities in excess of $100,000hat were incurred prior
to January 7, 2020 other than liabilities arising under the Lease

 

ARTICLE
2. REPRESENTATIONS AND WARRANTIES OF SELLERS

 

Except
as specifically disclosed to Buyer in a Disclosure Schedule, if any, received by Buyer from Sellers prior to execution of this
Agreement (“Disclosure Schedule”), Sellers each represent and warrant to Buyer as follows:

 

SECTION
2.1 ORGANIZATION. Provista is a company duly organized, validly existing and in good standing under the laws of Delaware and
has all necessary company powers to carry on its business as it is now being conducted. Provista is in good standing in each jurisdiction
in which it is so required.

 

SECTION
2.2 CAPITALIZATION. The authorized capital stock of Provista consists of 100 million shares of stock, par value $.0001 par
value per share, of which only the Provista Shares are issued and outstanding and, as of the date hereof. The Provista Shares
have been duly authorized and validly issued and are fully paid and nonassessable and are not subject to and were not issued in
violation of any preemptive rights. Sellers own the Provista Shares, beneficially and of record, free and clear of any Lien. There
are no outstanding (i) securities convertible into or exercisable or exchangeable for shares of Provista’ s capital stock
of or other voting or equity interests of Provista, (ii) options or other rights or agreements, commitments or understandings
of any kind to acquire Provista’s securities or other obligation to issue, transfer or sell, any shares of Provista’s
capital stock of or other voting or equity interests in Provista, (iii) voting trusts, proxies or other similar agreements or
understandings with respect to the voting of any shares of capital stock of or other voting or equity interests of Provista or
(iv) contractual obligations or commitments of any character restricting the transfer of, or requiring the registration for sale
of, any shares of Provista’s capital stock of or other voting or equity interests in Provista’s securities.

 

    	-4-

    	 

    

 

SECTION
2.3 OWNERSHIP. Upon delivery of the Purchase Price as set forth in Article 1 hereof, for the Provista Shares, good and valid
title to the Provista Shares will pass to Buyer, free and clear of any Liens. Ascenda is the sole beneficial and legal owner of
all outstanding capital stock of Provista, free and clear of all Encumbrances. Shareholder is the sole beneficial and legal owner
of all outstanding capital stock of Ascenda free and clear of all Encumbrances. There are no outstanding rights of any kind, direct
or indirect, contingent or otherwise, to purchase or otherwise acquire any shares of capital stock of Ascenda. As used in this
Agreement, “Encumbrance” means any mortgage, pledge, hypothecation, deed of trust, claim, infringement, right of first
refusal, preemptive right, voting right, community property interest, security interest, lien (including any tax lien), charge,
option, license, condition or other encumbrance or restriction of any nature whatsoever.

 

SECTION
2.4 AUTHORITY. Sellers each have the right, power and authority to execute and deliver this Agreement and any ancillary agreements
to which it is a party, consummate the transactions contemplated hereby and thereby, and have duly executed and delivered such
agreements. The execution and delivery of this Agreement and any ancillary agreements to which Sellers are a party and the consummation
of the transactions contemplated hereby and thereby have been duly approved by all requisite corporate action on the part of Sellers.
As against Sellers, this Agreement constitutes a valid and binding obligation, enforceable in accordance with its terms, except
as the enforceability thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws relating to
the rights of creditors generally and the availability of equitable relief.

 

SECTION
2.5 NO VIOLATION; CONSENTS AND APPROVALS. Neither the execution, delivery or performance by the Seller of this Agreement nor
the consummation by the Seller of the transactions contemplated hereby is an event that, of itself or with the giving of notice
or the passage of time or both, will: (i) violate or conflict with the provisions of the Articles of Incorporation or operating
agreement; (ii) violate or conflict with or result in any breach of or any default under, result in any termination or modification
of, or cause any acceleration of any obligation under, any contract, mortgage, indenture, agreement, or other instrument to which
Seller is a party or by which it is bound other than the Lease as set forth in Section 1.4 hereof, or by which it may be affected,
or result in the creation of any lien or encumbrance upon any of Seller’s assets; or (iii) violate any judgment, decree,
order, statute, rule or regulation applicable to Sellers.

 

SECTION
2.6 TITLE TO AND SUFFICIENCY OF ASSETS. Provista owns all rights, title and interest in and to all of its assets, free and
clear of all Encumbrances in excess of $10,000 other than payroll expenses and rents under the Lease.

 

SECTION
2.7 CONTRACTS. Each of the contracts to which Provista is a party will be assumed by the Buyer at the First Closing (the “Assumed
Contracts”), including the Lease. Each of the Assumed Contracts is legal, valid and in full force and effect, enforceable
in accordance with its terms. To Provista and Sellers’ knowledge, no other party to any Assumed Contract has taken the position
that any provision of such Assumed Contract is unenforceable. Provista, Sellers have not received notice of cancellation of or
default under or intent to cancel or call a default under any of the Assumed Contracts. Provista has performed all material obligations
required to be performed by it under the Assumed Contracts, and there exists no event or condition which with or without notice
or lapse of time or both would be a material breach or a material default on the part of Provista or, to the knowledge of Provista
and Sellers, on the part of any other party to such Assumed Contracts. Complete and accurate copies of all Assumed Contracts have
been provided to Buyer.

 

    	-5-

    	 

    

 

SECTION
2.8 INTELLECTUAL PROPERTY. Provista is the sole owner of all rights, titles and interests in and to its Intellectual Property,
free and clear of all Encumbrances. No notice has been received by Sellers are, and no claim or proceeding has been brought against
Provista, which challenges the validity or enforceability of such Intellectual Property or Provista’s complete and exclusive
ownership thereof. To Sellers’ knowledge, no third party is misappropriating, infringing or diluting any of such Intellectual
Property or violating any of Provista’s rights therein. Provista has taken all reasonable steps in accordance with normal
industry practice to protect its rights in its Intellectual Property. As used in this Agreement, “Intellectual Property”
means worldwide: (i) patents, patent applications and patent rights, including continuations, continuations-in-part, divisions,
reissues, renewals, reexaminations and extensions and applications therefore; (ii) trademarks, trade names, trade dress, logos,
service marks designs and general intangibles of like nature, registered or not, together with all common law rights and goodwill
related thereto; (iii) copyrights, moral rights and mask work rights, registered or not, and registrations and applications therefore;
(iv) inventions, know-how, methods, confidential business information, trade secrets and other proprietary information and intellectual
property rights (whether or not patentable or reduced to practice); (v) any and all trailers, pilots, scripts, ideas, plans, research,
designs, sponsorships and promotional materials treatments, summaries, videotapes, contracts, agreements and other electronic
or written documentation relating to, associated with, or comprising Provista’s assets; and (vi) rights to sue or make claims
for any past, present or future misappropriation or unauthorized use of any of the foregoing and the right to receive income,
royalties, damages and payments that are now will later become due with regard to the foregoing.

 

SECTION
2.9 INTERNET DOMAIN NAMES AND CONTENT. Provista is the sole registrant of all domain names used by it, has not licensed or
otherwise transferred any of the rights in such domain names to which a registrant thereof is entitled (or entered into any agreement
to do so), and has paid all registration fees relating to such domain names.

 

SECTION
2.10 TAX MATTERS. Within the times and in the manner prescribed by Law, Provista’s Tax returns required by Law have
been filed, and all Taxes and assessments required to be withheld or paid by Provista to any governmental authority have been
paid. As used in this Agreement, “Tax” means any federal, state, local or foreign income, gross receipts, license,
payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock,
franchise, profits, withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer,
registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest,
penalty, or addition thereto, whether disputed or not.

 

SECTION
2.11 LEGAL PROCEEDINGS; THIRD PARTY RIGHTS. There are no pending or, to Sellers’
knowledge, legal, administrative, arbitral or other proceedings (including disciplinary proceedings), suits, actions or
governmental or regulatory investigations of any nature (“Proceedings”) against or affecting Provista or
challenging the validity of the transactions contemplated by this Agreement. There is no injunction, order, judgment, decree
or regulatory restriction imposed upon Provista, and Provista is not a party to any Proceedings instituted by
it.

 

SECTION
2.12 COMPLIANCE WITH LAW. Provista is in compliance with all requirements of Law, and all requirements of all governmental
authorities having jurisdiction over it, the operation of its business, except to the extent the aggregate effect of the failure
to be in such compliance would not materially adversely affect the assets or Provista.

 

    	-6-

    	 

    

 

SECTION
2.13 LIABILITIES. Provista does not have any known obligations or liabilities in excess of $100,000, with exception of the
Lease.

 

SECTION
2.14 NON-CONTRAVENTION. Provided that all consents, approvals, authorizations and other actions described in Section 2.4 have
been obtained or taken, the execution and delivery by Sellers and each Transaction Document to which either is, or is specified
to be, a party, and the performance of its obligations hereunder and thereunder do not and will not (a) conflict with or breach
any provision of the organizational documents of the Shareholder or Ascenda, (b) conflict with or breach any provision of any
material applicable law, (c) require any consent of or other action by any person or entity (d) constitute a default or an event
that, with or without notice or lapse of time or both, would constitute a default under, or cause or permit termination, cancellation,
acceleration or other change of any right or obligation or the loss of any benefit under, any Permit, or any agreements to which
Provista is bound, or (e) result in the creation or imposition of any liens on any assets of the Provista.

 

ARTICLE
3. REPRESENTATIONS AND WARRANTIES OF BUYER

 

Except
as specifically disclosed to Sellers in this Agreement, Buyer represents and warrants to Sellers as follows:

 

SECTION
3.1 CORPORATE STATUS. Buyer is a corporation duly organized, validly existing, and in good standing under the laws of Israel.
Buyer is duly qualified to do business in each jurisdiction in which the character of and location of its assets or operations
makes qualification to do business as a foreign corporation necessary. Buyer has full corporate power to carry on its business
as it is now being conducted and as proposed to be conducted and to own and operate its assets. Buyer has full corporate power
and authority to execute and deliver this Agreement and perform the transactions contemplated hereby.

 

SECTION
3.2 CORPORATE ACTIONS. All corporate or other actions and proceedings necessary to be taken by or on the part of Buyer, its
directors and its shareholders in connection with the execution and delivery of this Agreement and the consummation of the transactions
contemplated by this Agreement have been duly and validly taken, and this Agreement has been duly and validly authorized, executed
and delivered by Buyer and constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance
with its terms.

 

SECTION
3.3 NO DEFAULTS. Neither the execution, delivery or performance by Buyer of this Agreement nor the consummation by Buyer of
the transactions contemplated hereby is an event that, of itself or with the giving of notice or the passage of time or both,
will: (i) violate or conflict with the provisions of the Articles of Incorporation or Bylaws of Buyer; (ii) violate or conflict
with or result in any breach of or any default under, result in any termination or modification of, or cause any acceleration
of any obligation under, any contract, mortgage, indenture, agreement, or other instrument to which Buyer is a party or by which
it is bound other than the Lease as set forth in Section 1.4 hereof, or by which it may be affected, or result in the creation
of any lien or encumbrance upon any of Buyer’s assets; or (iii) violate any judgment, decree, order, statute, rule or regulation
applicable to Buyer.

 

SECTION
3.4 CONSENTS AND APPROVALS. No consent, approval or authorization of, or declaration, filing or registration with any governmental
body is required to be made or obtained by Buyer in connection with the execution, delivery and performance of this Agreement
by Buyer or the consummation of the purchase of the Provista Shares by Buyer.

 

    	-7-

    	 

    

 

SECTION
3.5 OTHER CONSENTS. No consent of any person or entity is required to be obtained by Buyer to the execution, delivery and
performance of this Agreement by Buyer or the consummation of the purchase of the Provista Shares by Buyer.

 

SECTION
3.6 PURCHASE FOR INVESTMENT. Buyer is purchasing the Provista Shares solely for its own account for the purpose of investment
and not with a view to, or for sale in connection with, any distribution of any portion thereof in violation of any applicable
securities law.

 

SECTION
3.7 DILIGENCE. Buyer has undertaken an exhaustive review of the business and operations of Provista and is familiar with its
financial condition, operations, assets and liabilities. Buyer will have until the First Closing Date to conduct all additional
inspections and due diligence and satisfy itself regarding Provista and to inspect Provista’s facilities (the “Property”).
Buyer agrees to indemnify and hold Sellers harmless for any loss or damage to the Property or persons caused by Buyer or its agents
arising out of such physical inspections of the Property. Buyer expressly acknowledges that the sale of Provista as provided for
herein is made on an “AS IS” basis, and such provision shall survive the closing.

 

ARTICLE
4. FURTHER COVENANTS AND AGREEMENTS

 

SECTION
4.1 ANNOUNCEMENTS. The Parties shall consult with each other as to the form, substance and timing of any press release or
other public disclosure related to the transactions contemplated by this Agreement, and no such press release or other public
disclosure shall be made without the consent of the other parties hereto, which consent shall not be unreasonably withheld or
delayed; provided, however, that the parties may make such disclosure to the extent such disclosure is required by Law.

 

SECTION
4.2 TAXES. FURTHER ASSURANCES; CONSENTS. Subject to the terms and conditions of this Agreement, the parties shall use all
commercially reasonable efforts to take or cause to be taken, all actions (including the execution, delivery and filing of documents)
necessary, proper or advisable to consummate and make effective the transactions contemplated by this Agreement and any ancillary
agreements, including the obtaining of all required consents and approvals of governmental authorities and other third parties.
Notwithstanding the foregoing, no modification shall be made to any Assumed Contract to obtain any required consent without the
prior written consent of Buyer.

 

ARTICLE
5. CERTAIN COVENANTS

 

SECTION
5.1 CONDUCT OF THE BUSINESS. From the date hereof until the Second Closing, except as required by law or as otherwise expressly
permitted or contemplated by this Agreement, Buyer shall use commercially reasonable efforts to preserve Provista’s business
and maintain material relationships (contractual or otherwise). In connection therewith, Buyer shall not cause Provista to do
any of the following:

 

(a)
amend its certificate of incorporation or certificate of formation, or the by-laws or limited liability company operating agreement
as applicable, or take or authorize any action to wind up its affairs or dissolve;

 

(b) issue any securities;

 

    	-8-

    	 

    

 

(c)
amend or terminate its employee benefit plans, if any, in any material respect, establish, enter into or adopt any new arrangement
that would (if it were in effect on the date hereof) obligate Provista under an employee benefit plan (“Provista Benefit”)
or take any action with respect to any Provista Benefit Plan that would increase, accelerate or alter the liabilities of any Provista
Benefit Plan or reduce or impair the assets of any Provista Benefit Plan, take any action to increase, accelerate the payment
or vesting of, or fund or otherwise guarantee, freeze or secure the payment of compensation or benefits of any of its employees,
enter into, amend or otherwise modify any employment, severance, transaction-based, retention or other similar Contracts or arrangements
with any employees,

 

(d)
hire any employee, independent contractor, officer or director or terminate the employment of any of its employee or establish
any incentive compensation programs that relate in whole or part to compensation for any employee;

 

(e)
issue, sell or grant options, warrants or rights to purchase or subscribe to, enter into any arrangement or contract with respect
to the issuance or sale of, or redeem or repurchase any of its securities or make any changes (by combination, reorganization
or otherwise) in its capital structure;

 

(f)
sell, license, abandon, assign, transfer, pledge, or otherwise dispose of, or encumber, or grant any lien on any of its assets;

 

(g)
merge or consolidate with any other entity or acquire (including by merger, consolidation, acquisition of stock or assets, bulk
reinsurance) any assets or liabilities comprising a business or a segment, division or line of or business or any material amount
of property or assets in or of any other entity or create or acquire any Subsidiaries;

 

(h)
modify or amend in any material respect or recapture or terminate any material contracts or waive, release or assign any material
rights or claims thereunder or enter into any contract which would if entered into prior to the date hereof, have been a material
contract;

 

(i)
incur any Indebtedness, other than trade accounts payable and short-term working capital financing in each case, incurred in the
ordinary course of business or make any loans or advances;

 

(j)
default under any Indebtedness;

 

(k)
terminate, fail to renew or let lapse any permit necessary to conduct its business or fail to submit any reports, statements,
documents, registrations, filings or submissions to be filed with any governmental authority, in each case other than as would
not reasonably be expected, individually or in the aggregate, to be material;

 

(l)
enter into any new line of business, or introduce any new products or services, or change in any material respect existing products
or services, except as may be required by applicable Law;

 

(m)
terminate, cancel or amend, or cause the termination, cancellation or amendment of, any material insurance coverage (and any surety
bonds, letters of credit, cash collateral or other deposits related thereto required to be maintained with respect to such coverage)
maintained by it that is not replaced by comparable insurance coverage;

 

    	-9-

    	 

    

 

(n)
to the extent related to Taxes or Tax Returns, (i) settle or compromise any material Tax audit or forgo the right to any material
refund, offset or other reduction in Tax liability; (ii) change any methods, policies or practices of Tax accounting or methods
of reporting income or deductions for Tax purposes from those employed in the preparation of its most recently filed Tax Return;
(iii) amend any material Tax Return; (iv) enter into any material agreement with a Tax authority, or terminate any such agreement
entered into with a Tax authority that is in effect as of the date hereof; (v) alter or make any material Tax election; (vi) request
a ruling relating to Taxes, (vii) grant any power of attorney relating to Tax matters; (viii) prepare or file any Tax Return in
a manner that is not consistent with past practice or file a Tax Return of a type or in a jurisdiction not previously filed; or
(ix) request any ruling or similar guidance with respect to Taxes;

 

(o)
sell, transfer or otherwise dispose of any asset; or

 

(p)
promise, agree or commit to do any of the foregoing.

 

SECTION
5.2 ACCESS TO INFORMATION;BOOKS AND RECORDS

 

(a)
From the date hereof until the First Closing, Sellers shall and
shall cause Provista to (i) give Buyer, its counsel, financial advisors, auditors and other authorized Representatives reasonable
access to all of the offices, properties, contracts, books and records of Provista, not including access to IT systems, and to
the officers and employees of Provista whose assistance and expertise are reasonably necessary to assist Buyer in connection with
preparation to integrate Provista into Buyer’s organization following the First Closing, (ii) furnish to Buyer, its
counsel, financial advisors, auditors and other authorized Representatives such financial and operating data and other information
relating to Provista as such persons may reasonably request, and (iii) instruct the employees, counsel and financial advisors
of Sellers are to cooperate with Buyer in connection with Buyer’s investigation of Provista and preparation to integrate
Provista into Buyer’s organization following the First Closing.

 

(b)
Sellers shall have the right to retain copies of all books, data, files, information and records in any media (including, for
the avoidance of doubt, Tax Returns and other information and documents relating to tax matters) of Provista relating to periods
ending on or prior to the First Closing Date (i) relating to information (including employment and medical records) regarding
Provista’s employees, (ii) as may be required by any governmental authority, including pursuant to any applicable Law or
regulatory request, or (iii) as may be necessary for Sellers are or its Affiliates to perform their respective obligations pursuant
to this Agreement, in each case subject to compliance with all applicable privacy Laws. Buyer agrees that, with respect to all
original books, data, files, information and records of Provista existing as of the First Closing Date, it will (x) comply in
all material respects with all applicable Laws relating to the preservation and retention of records and (y) apply preservation
and retention policies that are no less stringent than those generally applied by Buyer to its own books and records.

 

ARTICLE
6 CONDITION’S PRECEDENT

 

SECTION
6.1 CONDITIONS TO THE BUYER’S OBLIGATIONS. The obligation of the Buyer hereunder is subject to the satisfaction, at
or before the First Closing Date of each of the following conditions provided that these conditions are for the Buyer’s
sole benefit and may be waived by the Buyer at any time in its sole discretion:

 

a)
The Sellers shall have executed this Agreement and the remaining Transaction Documents and delivered the same to the Sellers as
required by Article 1 and 2 hereof,

 

    	-10-

    	 

    

 

b)
The representations and warranties of the Sellers shall be true and correct in all material respects as of the date when made
and as of the First Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date), and the Sellers shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by the Transaction Documents be performed, satisfied or complied with by the Sellers are at or prior to the
First Closing Date, and

 

c)
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
Agreement; and

 

SECTION
6.2 CONDITIONS TO THE SELLER’S OBLIGATIONS. The obligations of the Sellers hereunder are subject to the
satisfaction, at or before the First Closing Date of each of the following conditions, provided that these conditions are for
the Sellers’ sole benefit and may be waived by the Sellers are at any time in its sole discretion:

 

a)
The Buyer shall have executed the Transaction Documents including all exhibits thereto and delivered the same to the Sellers,

 

b)
The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and
as of the First Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date) and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by the Buyer at or prior to the First Closing
Date,

 

c)
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by the
Transaction Documents,

 

d)
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Buyer including but not
limited to a change in the 1934 Act reporting status of the Buyer or the failure of the Buyer to be timely in its 1934 Act reporting
obligations, and

 

e)
The trading of Todos’ ordinary stock on the OTC Markets shall not have been suspended by the SEC.

 

    	-11-

    	 

    

 

ARTICLE
7. GENERAL PROVISIONS

 

SECTION
7.1 SUCCESSORS AND ASSIGNS. Except as otherwise expressly provided herein, this Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective successors and permitted assigns. The Sellers may assign its rights
hereunder without the prior written consent of the Buyer. Buyer may not assign its rights or obligations hereunder, and any such
attempted assignment or delegation without such consent shall be void.

 

SECTION
7.2 SEVERABILITY. Any provision of this Agreement which is held invalid or unenforceable in any jurisdiction shall, as to
that jurisdiction, be ineffective only to the extent of such invalidity or unenforceability and without rendering invalid or unenforceable
the remaining provisions of this Agreement or affecting the validity or enforceability of any of the provisions of this Agreement
in any other jurisdiction. If any provision of this Agreement is so broad as to be unenforceable, the provision shall be interpreted
to be only so broad as is enforceable.

 

SECTION
7.3 AMENDMENTS; WAIVERS. The provisions of this Agreement may be amended, modified or waived only by a written instrument
executed by the party against whom enforcement of the amendment, modification or waiver is sought. No waiver of any of the provisions
of this Agreement shall be deemed to be or shall constitute a waiver of any other provisions or agreements, whether or not similar.
No waiver shall be binding on the Parties unless executed in writing.

 

SECTION
7.4 NOTICES. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be: (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, email or email, addressed as set forth below or to such other address as such
party shall have specified most recently by written notice. Any notice or other communication required or permitted to be given
hereunder shall be deemed effective (a) upon hand delivery or delivery by email with accurate confirmation generated by the transmitting
computer, at the address or email address designated below (if delivered on a business day during normal business hours where
such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during
normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur. The addresses for such communications shall be the address designated below. Each party shall provide timely notice to
the other party of any change in address.

 

If
to Buyer:

 

Todos
Medical Ltd.

Derech
Menachem Begin street,

30th Floor,

Tel
Aviv, Israel 6701203

Phone: 011.972.526.420.126

Email:
gerald@todosmedical.com

 

    	-12-

    	 

    

 

If
to Seller:

 

Strategic
Investment Holdings, LLC

Galeria
de Artes y Ciencias I, #201 0

Dorado,
Puerto Rico 00646

 

With
a courtesy copy to:

 

Robert
Dev. Bunn, Esq.

5745
S.W. 75th Street, Suite 324

Gainesville,
Fl 32608

robert@strategiclaw.org;
bhamilton@securitieslawyer101.com; chris@thestrategicgroup.com.pr

 

SECTION
7.5 GOVERNING LAW. This Agreement and all questions relating to its validity, interpretation, performance and enforcement
shall be governed by and construed in accordance with the laws of Delaware without regard to that state or country’s conflict
of laws principles.

 

SECTION
7.6 JURISDICTION. Any proceeding relating to this Agreement or the subject matter hereof shall be brought only in federal
or state court in Delaware, and each party hereby generally and unconditionally submits to and accepts the jurisdiction of such
courts.

 

SECTION
7.7 ATTORNEYS FEES. In the event that any action is taken to enforce the terms of this Agreement, the prevailing party shall
be entitled to recover, in addition to other damages or remedies, its reasonable attorneys’ fees, court costs, and other
costs and expenses reasonably incurred in connection therewith, including but not limited to any reasonable attorneys’ fees,
court costs and other costs and expenses incurred in connection with seeking to recover the attorneys’ fees, court costs
and other costs and expenses of enforcement provided for by this paragraph.

 

SECTION
7.8 ENTIRE AGREEMENT. With respect to its subject matter, this Agreement (including the Disclosure Schedule, any other exhibits,
schedules, certificates or other instruments referred to herein, and any instruments delivered or executed in connection herewith
or pursuant hereto), together with any ancillary Agreements, constitutes the entire agreement of the parties, and supersedes all
prior agreements, understandings and representations, express or implied, oral or written, except as provided herein.

 

SECTION
7.9 COUNTERPARTS. This Agreement may be executed in two or more electronic signature counterparts, and PDF, electronic signatures
including DocuSign shall be deemed an original, and all of which together shall constitute one and the same agreement.

 

SECTION
7.10 INTERPRETATION. It is agreed and understood by the Parties that both Parties shall be deemed to have jointly drafted
this Agreement, and no inference or presumption shall be drawn against either of the Parties in the event of an alleged ambiguity.

 

SECTION
7.11 SURVIVAL. The representations of Sellers in this Agreement shall terminate on the date that Buyer delivers the Cash Deposit
to Sellers.

 

SECTION
7.12 EXPENSES. Except as specifically set forth herein, each party shall bear all of its expenses incurred in connection with
the transactions contemplated by this Agreement, including without limitation, accounting and legal fees incurred in connection
herewith.

 

    	-13-

    	 

    

 

SECTION
7.13 TIME IS OF THE ESSENCE. Time is of the essence in the performance of each of the obligations of the Parties and with
respect to all covenants and conditions to be satisfied by the Parties in the Transaction Documents and all documents, acknowledgments
and instruments delivered in connection herewith.

 

SECTION
7.14 CONFLICT WITH OTHER AGREEMENTS. If there is any conflict between the terms of this Agreement and any other agreement,
this Agreement shall prevail unless (i) such other agreement expressly states that it overrides this Agreement in the relevant
respect and (ii) the each of the Parties of this Agreement are either also parties to that other agreement or otherwise expressly
agree in writing that such other agreement shall override this Agreement in that respect.

 

SECTION
7.15 AUTHORITY. Each Party warrants and represents that it has the exclusive right, express authority, and full legal capacity
to execute this Agreement in the capacities designated below for the entities on whose behalf they are executing this Agreement.

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by their duly authorized signatories, effective
as of April 19, 2021.

 

PROVISTA
DIAGNOSTICS, INC.

 

	By:		 
	Name:	Robb
    Rill	 
	Title:	Director	 
	 	 	 
	ASCENDA
    BIOSCIENCES LLC	 
	 	 	 
	By:
    		 
	Name:	Robb
    Rill	 
	Title:	Member
    Representative of Strategic Investment Holdings, LLC	 
	 	 	 
	STRATEGIC
    INVESTMENT HOLDINGS, LLC	 
	 	 	 
	By:
    		 
	Name:	Robb
    Rill	 
	Title:	Manager	 
	 	 	 
	TODOS
    MEDICAL LTD	 
	 	 	 
	By:    		 
	Name:	Gerald
    E. Commissiong	 
	Title:	President
    & CEO	 

 

    	-14-Exhibit 10.2

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “SPA”) is entered into by and between Todos Medical Ltd., an Israeli company (the
“Company”), and Strategic Investment Holdings, LLC, a Nevada limited liability company (the “Holder” or
“Shareholder”) on the date set forth on the signature page hereto.

 

WHEREAS,
subject to the terms and conditions set forth in the Agreement (the “Provista Purchase Agreement” by and between the
Shareholder, Ascenda BioSciences LLC, a Delaware limited liability company (“Ascenda”) and Provista Diagnostics, Inc.,
a Delaware corporation (“Provista”) and the Company of even date herewith whereby the Company will purchase 100% of
the outstanding securities of Provista, the Company shall issue and sell to the Holder or Holder’s designees, (a) such number
of shares of the ordinary stock of the Company, par value NIS 0.01 per share, (the “Ordinary Stock”) with a Fair Market
Value of one million five hundred thousand dollars ($1,500,000), and (b) a promissory note with a Fair Market Value of $3,500,000
upon the terms and subject to the limitations and conditions set forth in this SPA and the Convertible Note. The Provista Purchase
Agreement, this Spa, the Convertible Promissory Note (the “Convertible Note”), Escrow Agreement (the “Escrow
Agreement”) and Security Agreement (the “Security Agreement”), each attached to the Provista Purchase Agreement
and each of even date herewith with all exhibits and schedules thereto, and other documents executed in connection with the transactions
contemplated hereby (collectively the “Transaction Documents”) each attached hereto and incorporated herein and made
a part hereof:

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this SPA, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Company and the Holder agree as follows:

 

1.
PURCHASE AND SALE.

 

1.1
The Ordinary Stock and Convertible Note. On the Closing Date (as defined below), the Company shall issue and deliver to the
Holder, such number of shares of the Ordinary Stock with a Fair Market Value (as defined herein) of $1,500,000 (the “Deposit
Shares”), and a promissory note (the “Convertible Note”) convertible into such number of shares of the Ordinary
Stock, with a Fair Market Value of $3,500,000 (the “Conversion Shares”) pursuant to the terms of the Convertible Note
attached to the SPA as Exhibit 3. The Ordinary Stock, the Convertible Note and the Ordinary Stock into which the Convertible Note
is exercisable into shall collectively be referred to herein as the “Securities”.

 

1.2
Intentionally omitted.

 

1.3 Consideration.
Pursuant to the terms of the Provista, the Company shall deliver the sum of $7,500,000 to Sellers. $1,500,000 of the Purchase
Price shall be paid by the Company with the Ordinary Stock with a Fair Market Value (as defined herein) of $1,500,000, and
$3,500,000 shall be paid with the Convertible Note to purchase shares of the Ordinary Stock with a Fair Market Value of
$3,500,000.

 

1.4
Closing Date. The First Closing shall occur on April 19, 2021 (the “First Closing Date”), and the Second Closing
shall occur on July 1, 2021 (the “Second Closing Date”) as set forth in the Provista Purchase Agreement.

 

    	-1-

    	 

    

 

1.5
Ownership. For the avoidance of doubt, on the First Closing Date, the Seller shall hold full right, title, and interest in
and to the Deposit Shares which shall include but not be limited to the beneficial ownership and right to the Deposit Shares.
For the avoidance of doubt, on Second Closing Date, the Seller shall hold full right, title, and interest in and to the Convertible
Note which shall include but not be limited to: (i) all contemplated conversion rights into the Company’s Ordinary Stock
arising under the Convertible Note, and (ii) the beneficial ownership and right to the Company’s Ordinary Stock issued upon
conversion of the Convertible Note.

 

2.
HOLDER’S REPRESENTATIONS AND WARRANTIES.

 

2.1
The Holder represents and warrants to the Company that it is an “accredited investor” as that term is defined in Rule
501(a) of Regulation D (an “Accredited Investor”) and acquiring the Securities for its own account and not with a
view towards, or for resale in connection with, the public sale or distribution thereof in violation of applicable securities
laws; provided, however, by making the representations herein, Holder does not agree, or make any representation or warranty,
to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities at any
time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

 

3.
REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

Except
as disclosed by the Company in the publicly filed SEC Documents (as defined in this SPA) the Company represents and warrants to
the Holder, as of the date hereof and the Closing Date, that:

 

3.1
Organization and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized,
validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority
(corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased,
used, operated and conducted. The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business
and is in good standing in every jurisdiction in which its ownership or use of property or the nature of the business conducted
by it makes such qualification necessary except where the failure to be so qualified or in good standing would not have a Material
Adverse Effect. “Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial
condition or prospects of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby
or by the agreements or instruments to be entered into in connection herewith. “Subsidiaries” means any corporation
or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or
other ownership interest.

 

3.2
Authorization; Enforcement. The Company has all requisite corporate power and authority to enter into and perform its obligations
under the Provista Purchase Agreement, this SPA, the Convertible Note, the Escrow Agreement and the Security Agreement and all
ancillary agreements, exhibits and schedules hereto and thereto (collectively the “Transaction documents”) and delivered
the same to the Seller and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance
with the terms hereof and thereof, the execution and delivery of the Transaction Documents by the Company and the consummation
by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Securities and the
issuance and reservation for issuance of the Conversion Shares issuable upon conversion of the Note) have been duly authorized
by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its
shareholders is required, the Transaction Documents have been duly executed and delivered by the Company, and each of the Transaction
Documents constitutes, and upon execution and delivery by the Company, each Transaction Document will constitute, a legal, valid
and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

    	-2-

    	 

    

 

3.3
Capitalization. As of the date hereof, the authorized capital stock of the Company, and number of shares issued and outstanding,
is as set forth in the Company’s most recent periodic report filed with the SEC. Except as disclosed in the SEC Documents
no shares are reserved for issuance pursuant to the Company’s stock option plans. Except as disclosed in the SEC Documents,
no shares are reserved for issuance pursuant to securities exercisable for, or convertible into or exchangeable for shares of
Ordinary Stock. All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued,
fully paid and nonassessable. No shares of capital stock of the Company are subject to preemptive rights or any other similar
rights of the shareholders of the Company or any liens or encumbrances imposed through the actions or failure to act of the Company
As of the effective date of the Transaction Documents, and except as disclosed in the SEC Documents, (i) there are no outstanding
options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings, claims or
other commitments or rights of any character whatsoever relating to, or securities, notes or rights convertible into or exchangeable
for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, (ii)
there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of
any of its or their securities under the 1933 Act and (iii) there are no anti-dilution or price adjustment provisions contained
in any security issued by the Company (or in any agreement providing rights to security holders) that will be triggered by the
issuance of any of the Securities. The SEC documents disclose all securities convertible into or exercisable for Ordinary Stock
of the Company and the material rights of the holders thereof in respect thereto.

 

3.4
Issuance of Shares. The Ordinary Stock and the Conversion Shares, upon conversion of the Convertible Note, as the case may be
duly authorized and the Conversion Shares reserved for issuance, in accordance with their respective terms. Upon issuance, the
Ordinary Stock and the Conversion Shares will be validly issued, fully paid and non-assessable, and free from all taxes, liens,
claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights
of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

    	-3-

    	 

    

 

3.5
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the
Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance
of the Securities) will not (i) conflict with or result in a violation of any provision of the Formation Documents or By-laws,
or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice
or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries
is a party and that is not filed as an SEC Document or other document filed with the SEC, or (iii) result in a violation of any
law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations
of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its
Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such
conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the
aggregate, have a Material Adverse Effect). Neither the Company nor any of its Subsidiaries is in violation of its Formation Documents,
By-laws or other organizational documents and neither the Company nor any of its Subsidiaries is in default (and no event has
occurred which with notice or lapse of time or both could put the Company or any of its Subsidiaries in default) under, and neither
the Company nor any of its Subsidiaries has taken any action or failed to take any action that would give to others any rights
of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any
of its Subsidiaries is a party or by which any property or assets of the Company or any of its Subsidiaries is bound or affected,
except for possible defaults as would not, individually or in the aggregate, have a Material Adverse Effect. Except as specifically
contemplated by this SPA and as required under the 1933 Act and any applicable state securities laws, the Company is not required
to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency, regulatory
agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver or perform any of
its obligations under the Transaction Documents in accordance with the terms hereof or thereof or to issue and sell the Securities
in accordance with the terms hereof and thereof.All consents, authorizations, orders, filings and registrations which the Company
is required to obtain pursuant to the preceding sentence have been obtained or effected on or prior to the date hereof. The Company
is not in violation of the listing requirements of the Principal Market (as defined in this SPA) and does not reasonably anticipate
that the Ordinary Stock will be delisted by the Principal Market in the foreseeable future. The Company and its Subsidiaries are
unaware of any facts or circumstances which might give rise to any of the foregoing.

 

3.6
SEC Documents; Financial Statements. Except for the Form 10-K for the year ended December 31, 2020, the Company has filed all
reports, schedules, forms, statements and other documents required to be filed by it with the SEC (all of the foregoing filed
prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other
than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).
As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Securities Exchange
Act of 1934, as amended (“1934 Act” or “Exchange Act”), and none of the SEC Documents, at the time they
were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under
applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof). As of
their respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such
financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently
applied, during the periods involved and fairly present in all material respects the consolidated financial position of the Company
and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for
the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).Except as set forth
in the financial statements of the Company included in the SEC Documents, the Company has no liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business, and (ii) obligations under contracts and commitments incurred
in the ordinary course of business and not required under generally accepted accounting principles to be reflected in such financial
statements, which, individually or in the aggregate, are not material to the financial condition or operating results of the Company.
The Company is subject to the reporting requirements of the 1934 Act.

 

    	-4-

    	 

    

 

3.7
Absence of Certain Changes. Since August 17, 2020, there has been no material adverse change and no material adverse development
in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act
reporting status of the Company or any of its Subsidiaries.

 

3.8
Absence of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such,
that could have a Material Adverse Effect. The public filings contain a complete list and summary description of any pending or,
to the knowledge of the Company, threatened proceeding against or affecting the Company or any of its Subsidiaries, without regard
to whether it would have a Material Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances
which might give rise to any of the foregoing.

 

3.9
Patents, Copyrights, etc. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all
patents, patent applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service
marks, service names, trade names and copyrights (“Intellectual Property”) necessary to enable it to conduct its business
as now operated (and, as presently contemplated to be operated in the future); there is no claim or action by any person pertaining
to, or proceeding pending, or to the Company’s knowledge threatened, which challenges the right of the Company or of a Subsidiary
with respect to any Intellectual Property necessary to enable it to conduct its business as now operated (and, as presently contemplated
to be operated in the future); to the best of the Company’s knowledge, the Company’s or its Subsidiaries’ current
and intended products, services and processes do not infringe on any Intellectual Property or other rights held by any person
and/or entity; and the Company is unaware of any facts or circumstances which might give rise to any of the foregoing. The Company
and each of its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of their
Intellectual Property.

 

3.10
No Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or
other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

 

    	-5-

    	 

    

 

3.11
Disclosure. No event or circumstance has occurred or exists with respect to the Company or any of its Subsidiaries or its or their
business, properties, prospects, operations or financial conditions, which, under applicable law, rule or regulation, requires
public disclosure or announcement by the Company but which has not been so publicly announced or disclosed.

 

3.12
Permits; Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses,
permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its
properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”), and there
is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of the Company
Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company
Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not reasonably be
expected to have a Material Adverse Effect. August 17, 2020, neither the Company nor any of its Subsidiaries has received any
notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices relating to possible
conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse Effect.

 

3.13
Intentionally omitted.

 

3.14
Intentionally omitted.

 

4.
COVENANTS.

 

4.1
Best Efforts. The parties shall use their reasonable best efforts to satisfy timely each of the conditions described in Section
6 and 7 of this SPA.

 

4.2
Form D; Blue Sky Laws. The Company agrees when applicable to timely file a Form D with respect to the Securities as required under
Regulation D and to provide a copy thereof to the Holder promptly after such filing. The Company shall, on or before the Closing
Date, take such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to the Holder
at the applicable closing pursuant to this SPA under applicable securities or “blue sky” laws of the states of the
United States (or to obtain an exemption from such qualification), and shall provide evidence of any such action so taken to the
Holder on or prior to the Closing Date.

 

4.3
Listing. The Company will obtain and, so long as the Holder owns any portion of the Securities, maintain the listing and trading
of its Ordinary Stock on the Principal Market, and will comply in all respects with the Company’s reporting, filing and
other obligations under the bylaws or rules of the Financial Industry Regulatory Authority (“FINRA”) and such exchanges,
as applicable. The Company shall promptly provide to the Holder copies of any notices it receives from the SEC, OTC Markets Group
and any other exchanges or quotation systems on which the Ordinary Stock is then listed regarding the continued eligibility of
the Ordinary Stock for listing on such exchanges and quotation systems, provided that it shall not provide any notices constituting
material nonpublic information. If at any time while Holder holds any portion of the Securities, the Company fails to maintain
the listing and trading and of its Ordinary Stock or fails in any way to comply with the Company’s reporting and filing
obligations such failure(s) will result in liquidated damages of one thousand dollars ($1,000),for each day that the Company’s
fails to maintain the listing and trading of its Ordinary Stock or fails to comply with the Company’s reporting filing obligations,
being immediately due and payable to Holder at its election in the form of cash payment.

 

    	-6-

    	 

    

 

4.4
Corporate Existence. So long as the Holder beneficially owns any Securities, the Company shall maintain its corporate existence
and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or
sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i)
assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith
and (ii) is a publicly traded corporation whose Ordinary Stock is listed for trading on Principal Market.

 

4.5
Securities Laws Disclosure; Publicity. The Company shall comply with applicable securities laws by filing a Current Report on
Form 8-K, within four (4) Trading Days following the execution date hereof, disclosing all the material terms of the transactions
contemplated hereby.

 

4.6
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by this SPA,
the Company covenants and agrees that neither it nor any other person acting on its behalf will provide the Holder or its agents
or counsel with any information that the Company believes constitutes material non-public information, unless prior thereto the
Holder shall have executed a written agreement regarding the confidentiality and use of such information. The Company understands
and confirms that the Holder shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

 

4.7
Intentionally omitted.

 

4.8
Intentionally omitted.

 

4.9
Piggyback Registration Rights. Subsequent to the Second Closing Date, the Company shall include the Ordinary Stock and the Conversion
Shares on: (i) the next registration statement under the Securities Act of 1933, as amended that the Company files with the SEC;
(ii) the subsequent registration statement if such previous registration statement is withdrawn, and (iii) any amendment to any
registration statement previously filed but not effective as of the date hereof.

 

    	-7-

    	 

    

 

5.
TRANSFER AGENT MATTERS.

 

5.1
Issuance and Exercise. At the Closing, the Company shall deliver the Ordinary Stock to the Seller and deliver the irrevocable
instructions (the “Irrevocable Transfer Agent Instructions”) attached hereto as Exhibit 2-B and made a part hereof
to Worldwide Stock Transfer, LLC, (the “Transfer Agent”) on its letterhead executed by the Company and the Transfer
Agent directing it to reserve 100,000,000 shares of the Ordinary Stock for issuance upon Conversion of the Note and to issue certificates,
registered in the name of the Holder or its nominee, for the Conversion Shares in such amounts as specified from time to time
by the Holder to the Company upon conversion of the Convertible Note, or any part thereof, in accordance with the terms thereof
(the “Irrevocable Transfer Agent Instructions”). In the event that the Company proposes to replace its transfer agent,
the Company shall provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions
in the form attached as Exhibit 2-B (including but not limited to the provision to irrevocably reserve shares of Ordinary Stock
in the Reserved Amount signed by the successor transfer agent (to the Company). Prior to registration of the Securities under
the 1933 Act or the date on which the Securities may be sold pursuant to Rule 144, Section 4(a)(1) of the Securities Act (“Section
4(a)(1)”), or other applicable exemption without any restriction as to the number of Securities as of a particular date
that can then be immediately sold, all such certificates shall bear the restrictive legend specified in this SPA. The Company
warrants that: (i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section, and stop
transfer instructions to give effect to hereof (in the case of the Securities, prior to registration of the Securities under the
1933 Act or the date on which the Securities may be sold pursuant to Rule 144, Section 4(a)(1), or other applicable exemption
without any restriction as to the number of Securities as of a particular date that can then be immediately sold), will be given
by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of
the Company as and to the extent provided in this SPA; (ii) it will not direct its transfer agent not to transfer or delay, impair,
and/or hinder its transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate representing
the Securities to be issued to the Holder or its assignees; and (iii) it will not fail to remove (or direct its transfer agent
not to remove or impair, delay, and/or hinder its transfer agent from removing) any restrictive legend (or to withdraw any stop
transfer instructions in respect thereof) on any certificate for any the Securities as and when required by this SPA and the Convertible
Note. If the Holder provides the Company with (i) an opinion of counsel in form, substance and scope customary for opinions in
comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under
the 1933 Act and such sale or transfer is effected or (ii) the Holder provides reasonable assurances that the Securities can be
sold pursuant to Rule 144, Section 4(a)(1), or other applicable exemption, the Company shall permit the transfer, and promptly
instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations
as specified by the Holder. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm
to the Holder, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges
that the remedy at law for a breach of its obligations under this Section may be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Section, that the Company will pay to the Holder, $15,000 per day
during the period in which the Transfer Agent or any successor transfer agent fails to comply with the terms of the Irrevocable
Transfer Agent Instructions. Additionally, Holder shall be entitled, in addition to all other available remedies, to an injunction
restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or
other security being required.

 

6.
DELIVERY, MATTERS IMPACTING THE SECURITIES.

 

6.1
Intentionally omitted.

 

6.2
Intentionally omitted.

 

6.3
Intentionally omitted.

 

6.4
Intentionally omitted.

 

6.5
Intentionally omitted.

 

6.6
Intentionally omitted.

 

    	-8-

    	 

    

 

6.7
Intentionally omitted.

 

6.8
Intentionally omitted.

 

7.
CONDITIONS TO THE COMPANY’S OBLIGATIONS.

 

The
obligation of the Company hereunder to issue and deliver the Securities to the Holder at the Closing is subject to the satisfaction,
at or before the Closing Date of each of the following conditions provided that these conditions are for the Company’s sole
benefit and may be waived by the Company at any time in its sole discretion:

 

a)
The Holder shall have executed the Transaction documents and delivered the same to the Company,

 

b)
The representations and warranties of the Holder shall be true and correct in all material respects as of the date when made and
as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date),
and the Holder shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions
required by the Transaction Documents be performed, satisfied or complied with by the Holder at or prior to the Closing Date,

 

c)
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on Provista; and

 

c)
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this
SPA.

 

8.
CONDITIONS TO THE HOLDER’S OBLIGATIONS.

 

The
obligations of the Holder hereunder is subject to the satisfaction, at or before the Closing Date of each of the following conditions,
provided that these conditions are for the Holder’s sole benefit and may be waived by the Holder at any time in its sole
discretion:

 

a)
The Company shall have executed the Transaction Documents and delivered the same to the Holder;

 

b)
The Irrevocable Transfer Agent Instructions shall have been delivered to and acknowledged in writing by the Company’s Transfer
Agent (a copy of which written acknowledgment shall be provided to Holder prior to Closing);

 

c)
The representations and warranties of the Company shall be true and correct in all material respects as of the date when made
and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific
date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and
conditions required by the Transaction Documents to be performed, satisfied or complied with by the Company at or prior to the
Closing Date. The Holder shall have received a certificate or certificates reasonably requested by the Holder including, but not
limited to certificates with respect to the Company’s Formation Documents, By-laws, and Board of Directors’ resolutions
relating to the transactions contemplated hereby;

 

    	-9-

    	 

    

 

d)
No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having
authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by the
Transaction Documents.

 

e)
No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but
not limited to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934
Act reporting obligations.

 

f)
The Ordinary Stock shall have been authorized for quotation on the Principal Market and trading of the Ordinary Stock on the Principal
Market shall not have been suspended by the Securities and Exchange Commission or the Principal Market.

 

9.
GOVERNING LAW; MISCELLANEOUS.

 

9.1
Governing Law. This SPA shall be governed by and construed in accordance with the laws of the State of Delaware without regard
to principles of conflicts of laws thereof or any other State. Any action brought by any party against any other party hereto
concerning the transactions contemplated by this SPA shall be brought only in the state courts located in the state of Delaware
or in the federal courts located in the state of Delaware. The parties to this SPA hereby irrevocably waive any objection to jurisdiction
and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based
upon forum non conveniens. The parties executing this SPA and other Transaction Documents referred to herein or delivered in connection
herewith on behalf of the Company agree to submit to the in personam jurisdiction of such courts and hereby irrevocably waive
trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable attorney’s fees and
costs. In the event that any provision of this SPA or any other Transaction Document delivered in connection herewith is invalid
or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.
Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any suit, action
or proceeding in connection with this SPA or any other Transaction Document contemplated hereby by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this SPA and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

 

    	-10-

    	 

    

 

9.2
Removal of Restrictive Legends. In the event that Holder has any shares of the Company’s Ordinary Stock bearing any restrictive
legends, and Holder, through its counsel or other representatives, submits to the Transfer Agent any such shares for the removal
of the restrictive legends thereon in connection with a sale of such shares pursuant to any exemption to the registration requirements
under the Securities Act, and the Company and or its counsel refuses or fails for any reason (except to the extent that such refusal
or failure is based solely on applicable law that would prevent the removal of such restrictive legends) to render an opinion
of counsel or any other documents or certificates required for the removal of the restrictive legends, then the Company hereby
agrees and acknowledges that the Holder is hereby irrevocably and expressly authorized to have counsel to the Holder render any
and all opinions and other certificates or instruments which may be required for purposes of removing such restrictive legends,
and the Company hereby irrevocably authorizes and directs the Transfer Agent to, without any further confirmation or instructions
from the Company, issue any such shares without restrictive legends as instructed by the Holder, and surrender to a common carrier
for overnight delivery to the address as specified by the Holder, certificates, registered in the name of the Holder or its designees,
representing the shares of Ordinary Stock to which the Holder is entitled, without any restrictive legends and otherwise freely
transferable on the books and records of the Company.

 

9.3
Filing Requirements. From the date of this SPA until the Holder no longer holds any portion of the Securities, the Company will
timely and voluntarily comply with all reporting requirements that are applicable to an issuer with a class of shares registered
pursuant to Section 12(g) of the 1934 Act, whether or not the Company is then subject to such reporting requirements and comply
with all requirements related to any registration statement filed pursuant to this SPA. The Company will use reasonable efforts
not to take any action or file any document (whether or not permitted by the 1933 Act or the 1934 Act or the rules thereunder)
to terminate or suspend such registration or to terminate or suspend its reporting and filing obligations under said acts until
Holder no longer holds any portion of the Securities, The Company will maintain the quotation or listing of its Ordinary Stock
on the OTCQX, OTCQB, OTC Pink, New York Stock Exchange, NASDAQ Stock Market, NYSE MKT, f/k/a American Stock Exchange, or other
applicable principal trading exchange or market for the Ordinary Stock (whichever of the foregoing is at the time the principal
trading exchange or market for the Ordinary Stock) (the “Principal Market”), and will comply in all respects with
the Company’s reporting, filing and other obligations under the bylaws or rules of the Principal Market, as applicable.
The Company will provide Holder with copies of all notices it receives notifying the Company of the threatened and actual delisting
of the Ordinary Stock from any Principal Market. As of the date of this SPA and the Closing Date, the OTCQB is the Principal Market.
So long as Holder holds any portion of the Securities, the Company will continue the listing or quotation of the Ordinary Stock
on a Principal Market and will comply in all respects with the Company’s reporting, filing and other obligations under the
bylaws or rules of the Principal Market.

 

9.4
Headings. The headings of this SPA are for convenience of reference only and shall not form part of, or affect the interpretation
of, this SPA.

 

9.5
Severability. In the event that any provision of this SPA is invalid or unenforceable under any applicable statute or rule of
law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified
to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any law shall
not affect the validity or enforceability of any other provision hereof.

 

    	-11-

    	 

    

 

9.6
Entire Agreement; Amendments. This SPA and the other Transaction Documents contain the entire understanding of the parties with
respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company
nor the Holder makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this
SPA may be waived or amended other than by an instrument in writing signed by the Holder.

 

9.7
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be
in writing and, unless otherwise specified herein, shall be: (i) personally served, (ii) deposited in the mail, registered or
certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or
(iv) transmitted by hand delivery, telegram, email or email, addressed as set forth in the Provista Purchase Agreement or to such
other address as such party shall have specified most recently by written notice. Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by email with accurate confirmation
generated by the transmitting computer, at the address or email address as designated in the Provista Purchase Agreement (if delivered
on a business day during normal business hours where such notice is to be received), or the first business day following such
delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on
the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or
upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be the address designated
in the Provista Purchase Agreement. Each party shall provide timely notice to the other party of any change in address.

 

9.8
Successors and Assigns. The Transaction Documents shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Neither the Company nor the Holder shall assign this SPA or any rights or obligations hereunder without the prior
written consent of the other. The Holder may assign its rights hereunder to any person that purchases any portion of the Securities
in a private transaction from the Holder or to any of its “affiliates,” as that term is defined under the 1934 Act,
without the consent of the Company.

 

9.9
Third Party Beneficiaries. This SPA is intended for the benefit of the parties hereto and their respective permitted successors
and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

9.10
Survival. The representations and warranties of the Company and the agreements and covenants set forth in the Transaction Documents
shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Holder. The
Company agrees to indemnify and hold harmless the Holder and all their officers, directors, employees and agents for loss or damage
arising as a result of or related to any breach or alleged breach by the Holder of any of its representations, warranties and
covenants set forth in this SPA or any of its covenants and obligations under the Transaction Documents, including advancement
of expenses as they are incurred.

 

    	-12-

    	 

    

 

9.11
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and
shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of the Transaction Documents and the consummation of the
transactions contemplated hereby.

 

9.12
No Strict Construction. The language used in the Transaction Documents will be deemed to be the language chosen by the parties
to express their mutual intent, and no rules of strict construction will be applied against any party.

 

9.13
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder
by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy
at law for a breach of its obligations under this SPA will be inadequate and agrees, in the event of a breach or threatened breach
by the Company of the provisions of this SPA, that the Holder shall be entitled, in addition to all other available remedies at
law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing
or curing any breach of this SPA and to enforce specifically the terms and provisions hereof, without the necessity of showing
economic loss and without any bond or other security being required.

 

9.14
Counterparts. The Transaction Documents may be executed in any number of counterparts, each of which when so executed and delivered
shall be deemed to be an original and all of which together shall be deemed to be one and the same agreement. Any signature transmitted
by e-mail, or other electronic means shall be deemed to be an original signature.

 

9.15
Time is of the Essence. Time is of the essence in the performance of each of the obligations of the Parties and with respect to
all covenants and conditions to be satisfied by the Parties in the Transaction Documents and all documents, acknowledgments and
instruments delivered in connection herewith.

 

IN
WITNESS WHEREOF, the undersigned Holder and the Company have caused this SPA to be duly executed as of April 19, 2021.

 

STRATEGIC
INVESTMENT HOLDINGS, LLC

 

	By:
    		 
	Name:	Robb
    Rill	 
	Title:	Manager	 
	 	 	 
	TODOS
    MEDICAL LTD	 
	 	 	 
	By:
    		 
	Name:	Gerald
    Commissiong	 
	Title:	President
    and CEO	 

 

    	-13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]